Suppr超能文献

骨髓和脐带来源扩展间充质基质细胞治疗慢性脊髓损伤患者的安全性和潜在疗效:一项 I/II 期研究。

Safety and potential efficacy of expanded mesenchymal stromal cells of bone marrow and umbilical cord origins in patients with chronic spinal cord injuries: a phase I/II study.

机构信息

School of Medicine, University of Jordan, Amman, Jordan.

The University of Jordan School of Medicine, Amman, Jordan.

出版信息

Cytotherapy. 2024 Aug;26(8):825-831. doi: 10.1016/j.jcyt.2024.03.480. Epub 2024 Apr 10.

Abstract

BACKGROUND AIMS

Spinal cord injury (SCI) affects patients' physical, psychological, and social well-being. Presently, treatment modalities for chronic SCI have restricted clinical effectiveness. Mesenchymal stromal cells (MSCs) demonstrate promise in addressing nervous tissue damage. This single-center, open-label, parallel-group randomized clinical trial aimed to assess the safety and efficacy of intraoperative perilesional administration of expanded autologous bone marrow-derived MSCs (BMMSCs), followed by monthly intrathecal injections, in comparison to monthly intrathecal administration of expanded allogeneic umbilical cord-derived MSCs (UCMSCs) for individuals with chronic SCI.

METHODS

Twenty participants, who had a minimum of 1 year of SCI duration, were enrolled. Each participant in Group A received perilesional BMMSCs, followed by monthly intrathecal BMMSCs for three injections, while Group B received monthly intrathecal UCMSCs for three injections. Safety and efficacy were evaluated using the American Spinal Cord Injury Association (ASIA) score for at least 1 year post the final injection. Statistical analysis was conducted using the Wilcoxon signed-rank test.

RESULTS

Group A comprised 11 participants, while Group B included 9. The mean follow-up duration was 22.65 months. Mild short-term adverse events encompassed headaches and back pain, with no instances of long-term adverse events. Both groups demonstrated significant improvements in total ASIA scores, with Group A displaying more pronounced motor improvements.

CONCLUSIONS

Our findings indicate that perilesional administration of expanded autologous BMMSCs, followed by monthly intrathecal BMMSCs for three injections, or monthly intrathecal UCMSCs for three injections appear to be safe and hold promise for individuals with chronic SCI. Nonetheless, larger-scale clinical trials are imperative to validate these observations.

摘要

背景目的

脊髓损伤(SCI)影响患者的身体、心理和社会福祉。目前,慢性 SCI 的治疗方法疗效有限。间充质基质细胞(MSCs)在解决神经组织损伤方面显示出前景。本单中心、开放标签、平行组随机临床试验旨在评估术中病变周围给予扩增自体骨髓源性 MSCs(BMMSCs),随后每月鞘内注射,与每月鞘内给予扩增同种异体脐带源性 MSCs(UCMSCs)相比,对慢性 SCI 患者的安全性和疗效。

方法

共纳入 20 名 SCI 持续时间至少 1 年的参与者。A 组的每位参与者接受病变周围 BMMSCs 治疗,随后每月鞘内注射 BMMSCs 三次,B 组接受每月鞘内注射 UCMSCs 三次。至少在最后一次注射后 1 年,使用美国脊髓损伤协会(ASIA)评分评估安全性和疗效。使用 Wilcoxon 符号秩检验进行统计分析。

结果

A 组包括 11 名参与者,B 组包括 9 名参与者。平均随访时间为 22.65 个月。轻度短期不良事件包括头痛和背痛,无长期不良事件发生。两组的总 ASIA 评分均有显著改善,A 组的运动功能改善更为明显。

结论

我们的研究结果表明,病变周围给予扩增自体 BMMSCs,随后每月鞘内注射 BMMSCs 三次,或每月鞘内注射 UCMSCs 三次,似乎是安全的,对慢性 SCI 患者有一定的疗效。然而,需要更大规模的临床试验来验证这些观察结果。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验